Stock Events

Stock Events

Santhera Pharmaceuticals 

€17.9
0
-€0.24-1.32% Friday 19:55

Statistics

Day High
18.6
Day Low
17.86
52W High
139.6
52W Low
10.02
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28AprExpected
Q2 2025
Next
-3.24
-2.91
-2.58
-2.24
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow S3F0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, similar to Santhera's focus on Duchenne muscular dystrophy and other mitochondrial and neuromuscular diseases.
PTC Therapeutics
PTCT
Mkt Cap5.7B
PTC Therapeutics is involved in the development of drugs for the treatment of rare disorders, including Duchenne muscular dystrophy, which is a direct competition to Santhera's product pipeline.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare genetic disorders that overlap with Santhera's target market.
Solid Biosciences
SLDB
Mkt Cap736.95M
Solid Biosciences is focused on developing therapies for Duchenne muscular dystrophy, directly competing with Santhera's efforts in the same area.
Wave Life Sciences
WVE
Mkt Cap1.37B
Wave Life Sciences is working on genetically defined diseases, including Duchenne muscular dystrophy, positioning it as a competitor in the same niche as Santhera.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is engaged in the development of gene-based therapies for serious diseases, including treatments that could potentially compete with Santhera's pipeline for neuromuscular and mitochondrial diseases.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine operates in the genome editing field, aiming to develop therapies for a range of serious diseases, including those in Santhera's focus area, making it a competitor.
Novartis
NVS
Mkt Cap297.32B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for neuromuscular diseases, among others, competing with Santhera on a larger scale.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a global biopharmaceutical company with a diverse portfolio, including research in rare diseases, which could potentially compete with Santhera's niche market.

About

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Show more...
CEO
Dr. Thomas Meier Ph.D.
Employees
78
Country
CH
ISIN
CH1276028821

Listings

OTC Link
US
SPHDF
STU
DE
S3F0.STU
F
DE
S3F0.F
LSE
GB
0QN1.LSE

0 Comments

Share your thoughts

FAQ

What is Santhera Pharmaceuticals stock price today?▼
The current price of S3F0.STU is €17.9 EUR — it has decreased by -1.32% in the past 24 hours. Watch Santhera Pharmaceuticals stock price performance more closely on the chart.
What is Santhera Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Santhera Pharmaceuticals stocks are traded under the ticker S3F0.STU.
Is Santhera Pharmaceuticals stock price growing?▼
S3F0.STU stock has risen by +2.29% compared to the previous week, the month change is a -5.19% fall, over the last year Santhera Pharmaceuticals has showed a -87.18% decrease.
When is the next Santhera Pharmaceuticals earnings date?▼
Santhera Pharmaceuticals is going to release the next earnings report on April 28, 2026.
What were Santhera Pharmaceuticals earnings last quarter?▼
S3F0.STU earnings for the last quarter are -3.24 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Santhera Pharmaceuticals have?▼
As of April 11, 2026, the company has 78 employees.
In which sector is Santhera Pharmaceuticals located?▼
Santhera Pharmaceuticals operates in the Health Care sector.
When did Santhera Pharmaceuticals complete a stock split?▼
Santhera Pharmaceuticals has not had any recent stock splits.
Where is Santhera Pharmaceuticals headquartered?▼
Santhera Pharmaceuticals is headquartered in Pratteln, CH.